Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
Bio2RDF identifier
NCT00602147
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00602147
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
biospec retention [clinicaltrials_vocabulary:biospec-retention]
Samples With DNA
biospec_descr [clinicaltrials_vocabulary:biospec_descr]
Blood sample or cheek cells will be collected.
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Studying blo ...... eceiving high-dose melphalan.
brief title [clinicaltrials_vocabulary:brief-title]
Studying Common Genetic Mutati ...... Receiving High-Dose Melphalan
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2010-04-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... for genotype
analysis.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2008-01-22T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
refractory multiple myeloma
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-03-12T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00602147
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Genetic Analysis of Toxicity Associated With High-Dose Melphalan
org study id [clinicaltrials_vocabulary:org-study-id]
VICC HEM 0750
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2009-01-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
VU-VICC-HEM-0750
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2007-07-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-03-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
The original PI on this study left VICC, thus study was closed.
identifier
clinicaltrials:NCT00602147
title
Studying Common Genetic Mutati ...... Receiving High-Dose Melphalan
@en